Penta HIV Trials | PENTA 8 (PERA)

A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1 infected children: the PERA (PENTA 8)

2006

Authors: Aboulker J-P, Babiker A, Bacheler L, et al. On behalf of the PENTA 8 study group

Published in: Antivir Ther. 2006;11(7):857-867

Objective To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure.

Methods Children aged 3 months-18 years switching antiretroviral therapy (ART) with HIV-1 RNA >

A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (PENTA 8) trial

2005

Authors: Giaquinto C, Green H, De Rossi A, et al. On behalf of the PENTA 8 study group.

Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Oral and poster presentation WeOa0106

Abstract The development of resistance to antiretroviral drugs is considered to be an important cause of treatment failure in HIV infection.

1